Personalising care in operable pancreas cancer. GAP-T: a study of imaging and molecular biomarkers to guide treatment of patients receiving preoperative chemotherapy followed by surgery.

可手术胰腺癌的个性化护理。

• 批准号: nhmrc : 1026563
• 负责人: Dr David Chang
• 金额: $ 27.03万
• 依托单位: The University of Sydney
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2012
• 资助国家: 澳大利亚
• 起止时间: 2012-01-01 至 2015-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/personalising-care-operable-followed-surgery/110505
• 关键词: Personalising; care; operable; pancreas; cancer.

We are studying ways to improve how we treat patients with pancreatic cancer. We will use a novel imaging tool, the PET scanner, to show where active cancer is and how quickly and how well a new drug combination (gemcitabine and nab-paclitaxel) is affecting the cancer. We will also study if measuring the expression of specific proteins (SPARC and hENT1) in the cancer affects the outcome and will allow us to determine ahead of time which patients will benefit most from the drugs.

我们正在研究改善治疗胰腺癌患者的方法。我们将使用一种新的成像工具，PET扫描仪，来显示活动性癌症的位置，以及一种新的药物组合（吉西他滨和nab-紫杉醇）对癌症的影响有多快和多好。我们还将研究测量癌症中特定蛋白质（SPARC和hENT1）的表达是否会影响结果，并使我们能够提前确定哪些患者将从药物中获益最多。